NCT00988117View on ClinicalTrials.gov

The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Parkinsons Disease With DementiaParkinsons Disease With Mild to Moderate Memory and/or Thinking Problems
Interventions
DRUG

Rivastigmine Patch 9.5 cm2

Subjects will be started on a 5cm2/24hr rivastigmine patch. After 4 weeks, the dose will be increased to a recommended target dose of 9.5cm2/24hr patch for 8 additional weeks.

Trial Locations (1)

94117

UCalifornia SF, San Francisco

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of California, San Francisco

OTHER